Developing a short form of the Awe Experience Scale (AWE-SF) in psychedelic samples

PLoS One. 2024 Dec 4;19(12):e0314469. doi: 10.1371/journal.pone.0314469. eCollection 2024.

Abstract

This study aimed to develop and validate a short-form version of the AWE-S (AWE-SF) within psychedelic samples, to reduce participant burden while maintaining psychometric integrity. Across five studies, we first replicated the original six-factor structure of the AWE-S through exploratory and confirmatory factor analyses (Study 1), leading to the creation of the 12-item AWE-SF (Study 2-3). We then established the AWE-SF's initial and predictive validity by correlating it with relevant emotional, psychedelic, and well-being outcomes (Study 4-6). The AWE-SF demonstrated strong positive associations with positive emotions and was also linked to openness to experience. Moreover, the AWE-SF effectively predicted both mystical-type and challenging psychedelic experiences, as well as long-term well-being outcomes such as life satisfaction and psychological richness. In particular, the facets of connection and vastness were associated with positive emotional states and mystical-type experience, while accommodation and self-loss were associated with negative emotional states and challenging psychedelic experience. These findings suggest that the AWE-SF is a robust, reliable, and accessible tool for measuring awe experience.

MeSH terms

  • Adolescent
  • Adult
  • Emotions* / drug effects
  • Factor Analysis, Statistical
  • Female
  • Hallucinogens*
  • Humans
  • Male
  • Middle Aged
  • Personal Satisfaction
  • Psychometrics*
  • Surveys and Questionnaires
  • Young Adult

Substances

  • Hallucinogens

Grants and funding

The author(s) received no specific funding for this work.